Health Care

SENATE BILL 1767
By Pody

HOUSE BILL 1852
By Fritts
HB1852
010844
- 1 -

AN ACT to amend Tennessee Code Annotated, Title 33;
Title 37; Title 44; Title 47; Title 49; Title 53; Title 63
and Title 68, relative to health.

WHEREAS, substantial evidence reveals that mRNA pharmaceutical interventions are
ineffective at preventing infection, transmission, severe illness, hospitalization, or death, with
additional concerns over rapidly waning immunity and heightened risks associated with their
use; and
WHEREAS, substantial evidence indicates that mRNA pharmaceutical interventions are
associated with widespread and severe adverse events, including thousands of documented
injuries, underreported cases, and significant increases in pharmaceutical-related harm and
excess mortality; and
WHEREAS, numerous health organizations, medical professionals, and international
governments have called for an immediate moratorium on mRNA pharmaceutical interventions,
citing serious health concerns, documented risks, and the urgent need for comprehensive
investigations into their safety and efficacy; and
WHEREAS, mRNA pharmaceutical interventions exhibit wide-area biodistribution and
bioaccumulation, with spike proteins and mRNA sequences detected in critical organs such as
the brain, heart, and endocrine glands, as well as in the blood, placenta, and fetus, raising
serious concerns about systemic and long-term effects on human health; and
WHEREAS, components of mRNA vaccines, including spike proteins and mRNA
sequences, have been shown to persist in the body far longer than initially claimed, up to 245
days in some cases, raising critical concerns about their long-term effects on human health and
systemic stability; and

- 2 - 010844

WHEREAS, mRNA pharmaceutical interventions have been strongly associated with
severe cardiovascular and thrombotic events, including myocarditis, pericarditis, blood clots,
and cardiomyopathy, with documented increases in adverse event reports and sudden deaths,
particularly among young individuals, raising urgent concerns about their safety and widespread
use; and
WHEREAS, mRNA pharmaceutical interventions have been linked to severe lung and
respiratory complications, including increased risks of asthma, acute respiratory distress
syndrome, pulmonary fibrosis exacerbation, and systemic respiratory disorders, highlighting
significant concerns about their impact on respiratory health; and
WHEREAS, mRNA pharmaceutical interventions have been implicated in endocrine
disruptions, including the occurrence of abnormal blood glucose levels, raising concerns about
their effects on metabolic and hormonal health; and
WHEREAS, mRNA pharmaceutical interventions have been associated with significant
pediatric risks, including increased disease prevalence in infants, heightened rates of heart
disease, anxiety, depression, and adverse neurological effects in children, as well as alarming
impacts on offspring development, raising profound concerns about their safety in vulnerable
populations; and
WHEREAS, mRNA pharmaceutical interventions have been associated with cancer-
related risks, including the presence of spike proteins that may support cancer cell survival,
contamination with SV40 sequences linked to cancer, stimulation of tumor growth, and
significant increases in cancer diagnoses and deaths following mass vaccination campaigns,
raising grave concerns about their safety and long-term effects; and
WHEREAS, mRNA pharmaceutical interventions have been linked to a range of severe
neurological effects, including Guillain-Barré syndrome, seizures, autoimmune brain
inflammation, neuromuscular diseases, and increased risks of neurological disorders such as

- 3 - 010844

Bell's palsy and encephalitis, raising critical concerns about their impact on the nervous system
and overall brain health; and
WHEREAS, mRNA pharmaceutical interventions have been associated with lymphatic
system disorders, including vaccine-induced lymphadenopathy and axillary lymph node
abnormalities, raising concerns about their effects on immune system function and lymphatic
health; and
WHEREAS, mRNA pharmaceutical interventions have been linked to an increase in
psychological disorders, including anxiety, depression, and new-onset psychosis, exacerbating
mental health concerns; and
WHEREAS, mRNA pharmaceutical interventions have been associated with the onset of
diabetes-related conditions, including new-onset Type 1 and Type 2 diabetes, transient
hyperglycemia, and central diabetes insipidus, raising concerns about their impact on metabolic
health and glycemic regulation; and
WHEREAS, mRNA pharmaceutical interventions have been linked to a concerning
incidence of sleep disorders, raising additional health concerns about their potential neurological
and systemic side effects; and
WHEREAS, mRNA pharmaceutical interventions have been associated with nerve-
related complications, including radial nerve motor palsy and trigeminal neuralgia, raising
concerns about their effects on the peripheral nervous system; and
WHEREAS, mRNA pharmaceutical interventions have been liked to a wide range of
dermatological and skin-related adverse events, including new-onset and exacerbation of
psoriasis, vitiligo, severe dermatitis, alopecia, toxic epidermal necrolysis, and other inflammatory
and autoimmune skin conditions, raising serious concerns about their impact on dermatological
health; and

- 4 - 010844

WHEREAS, mRNA pharmaceutical interventions have been associated with serious
ocular complications, including eye inflammation, blood supply deficiencies, blindness, white dot
syndrome, and Henoch-Schönlein purpura, raising concerns about their safety and impact on
vision and ocular health; and
WHEREAS, mRNA pharmaceutical interventions have been linked to significant
reproductive and fertility concerns, including menstrual irregularities, higher rates of miscarriage,
functional lactation disorders, fetal exposure risks, and negative impacts on sperm quality,
raising substantial concerns about their effects on reproductive health and outcomes; and
WHEREAS, mRNA pharmaceutical interventions have been associated with a broad
range of immune system and autoimmune disorders, including reduced immune function, lupus,
rheumatoid arthritis, autoimmune encephalitis, and the onset or exacerbation of various
autoimmune diseases, raising critical concerns about their impact on immune regulation and
systemic health; and
WHEREAS, self-amplifying mRNA (samRNA) vaccines pose significant risks, including
the potential for injecting live, self-replicating viruses into recipients due to contamination, and
the production of even more toxic spike proteins in the body compared to regular mRNA
vaccines, raising serious concerns about their safety and regulatory oversight; and
WHEREAS, there have been no long-term, double-blind, placebo-controlled, randomized
studies to assess the safety of mRNA and self-amplifying mRNA (samRNA) pharmaceutical
interventions in agricultural produce, despite mounting evidence of severe adverse effects in
humans, animals, and the environment, including immune system disruptions, cardiovascular
risks such as SD40 and DNA integration, raising significant concerns about the unknown and
potentially harmful impact of these technologies on food safety, animal welfare, and human
health; and

- 5 - 010844

WHEREAS, readily available, safe, and effective FDA-approved treatments, such as
budesonide, ivermectin, hydroxychloroquine, and monoclonal antibodies, have demonstrated
significant efficacy in the early and late treatment of COVID-19, with expert testimony and
clinical studies confirming their potential to prevent severe outcomes and reduce mortality,
raising concerns about the prioritization of experimental vaccines over these proven therapies;
now, therefore,
BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE:
SECTION 1. This act is known and may be cited as the "Tennessee mRNA
Pharmaceutical Sovereignty and Safety Act."
SECTION 2. Tennessee Code Annotated, Title 63, Chapter 1, Part 1, is amended by
adding the following as a new section:
(a) As used in this section:
(1) "Healthcare provider" means an individual who is licensed, registered,
certified, or otherwise permitted under this title or title 68 to engage in the
provision of health care or veterinary medicine in the course of a profession; and
(2) "mRNA vaccine or vaccine material":
(A) Means a substance to stimulate the production of antibodies
and provide immunity against disease by introducing messenger
ribonucleic acid (mRNA) that corresponds to a viral protein; and
(B) Includes a self-amplifying mRNA (samRNA) vaccine or
vaccine material.
(b) An individual, including a healthcare provider, shall not administer to any
human or animal in this state a vaccine or other injectable solution that contains an
mRNA vaccine or vaccine material.
(c)

- 6 - 010844

(1) A violation of subsection (b) is a Class A misdemeanor, punishable
only by a fine of up to two thousand five hundred dollars ($2,500) per violation.
The administration of each vaccine or other injectable solution in violation of
subsection (b) constitutes a separate violation.
(2) In addition to subdivision (c)(1), a healthcare provider who violates
subsection (b) may be subject to administrative sanction or penalty by the
healthcare provider's regulatory entity, up to and including revocation of the
healthcare provider's license, registration, certification, or other permission to
engage in the provision of health care or veterinary medicine in this state.
SECTION 3. This act takes effect January 1, 2027, the public welfare requiring it.